Company intelligence / Profile preview

Shanghai EGT Synbio Group

Ownership: Private
Development stage: Commercial

Overview

Shanghai EGT Synbio Group has commercialized high-purity, bio-fermented ergothioneine with FDA GRAS status in the US. Human clinical data confirm safety and efficacy for use as a dietary supplement ingredient. The company is recognized for its innovation in large-scale biological production of ergothioneine, winning industry awards and supplying global markets.

Therapeutic areas: ImmunologyOtherCardiovascularOphthalmologyNeurology
Modalities: Small molecule
Industry: Non-Drug Biotech

Drug pipeline

1 asset

ergothioneine

Commercial

Indications: Aging, Neurodegeneration, Alzheimer's disease

Partnerships

SGS Nutrasource / GRAS AssociatesAbinopharm Inc.

Beyond the preview

Go deeper on Shanghai EGT Synbio Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai EGT Synbio Group.

Explore the full profile